Weight Management • Fresno, CA

Weight management that feels calm, clinical, and elevated.

If medication is appropriate, we may discuss GLP-1 therapies such as semaglutide as part of a broader plan— nutrition, movement, sleep, and follow-up that supports lasting change.

Book Appointment Read FAQs
Evidence base: FDA (GLP-1 safety info) · STEP 1 Trial (NEJM) · CDC (Obesity)
Metabolic health
Body composition
Long-term sustainability
Weight management consultation
Private, clinician-guided care designed for real life.
What semaglutide is

Semaglutide as part of comprehensive care

Semaglutide is a prescription medication in the GLP-1 receptor agonist class. Depending on the product and indication, it may be used for type 2 diabetes management and/or chronic weight management in certain adults, alongside lifestyle changes. We determine candidacy based on your medical history, labs, goals, and safety. FDA

Important: We do not position this as “aesthetic enhancement.” Our focus is evidence-based weight and cardiometabolic risk management—safely and responsibly.
  • Personalized nutrition + activity plan
  • Medication discussion when appropriate
  • Ongoing follow-up to support sustainability
What the research shows

Potential outcomes—varies by individual

Weight reduction support

In clinical trials for chronic weight management, semaglutide (with lifestyle intervention) was associated with meaningful weight loss for many participants. STEP 1 (NEJM)

Appetite and satiety

GLP-1 therapies can reduce appetite and increase fullness, which may help support a calorie deficit—when paired with a structured plan. NIDDK

Cardiometabolic focus

Weight management is not just a number. We track blood pressure, glucose markers, lipids, sleep, and energy—building toward long-term risk reduction. CDC

Honest expectations: Results vary. Medication is one tool—most durable outcomes come from consistency, follow-up, and addressing the drivers (nutrition, sleep, stress, strength, and routine).
The experience

What to expect at Valley Natural Health

01
Consult: goals, history, current medications, and prior attempts.
02
Assessment: vitals + labs as appropriate to understand metabolic drivers.
03
Plan: nutrition + movement + sleep strategy; medication options when appropriate.
04
Follow-up: adjust dosing/plan, manage side effects, track progress safely.
Safety & prescribing notes

GLP-1 medications can have side effects and are not appropriate for everyone. Common side effects include gastrointestinal symptoms. There are important warnings and contraindications (including a boxed warning for certain semaglutide products). We review your full history and discuss risks/benefits before prescribing. FDA

Book Appointment
Fresno, CA • Private care • Evidence-based approach
FAQ

Semaglutide & weight management FAQs

Is semaglutide for diabetes or weight loss?
Semaglutide products may be indicated for type 2 diabetes and/or chronic weight management depending on the specific medication and patient criteria. We’ll review what’s appropriate for your medical profile.
Source: FDA
How does it work?
GLP-1 receptor agonists influence appetite and satiety signals, which can help reduce calorie intake when paired with lifestyle changes.
Source: NIDDK
What kind of results should I expect?
Results vary. Clinical trials in chronic weight management showed meaningful average weight loss with semaglutide plus lifestyle intervention for many participants, but individual outcomes differ and follow-up matters.
Source: STEP 1 (NEJM)
Are there side effects or risks?
GLP-1 medications can cause side effects and have warnings/contraindications. We screen carefully, explain risks, and monitor follow-up.
Source: FDA
Do I have to stay on it forever?
That depends on your goals, response, and medical context. We’ll discuss long-term strategy, tapering considerations, and how lifestyle supports maintenance.
Weight management in Fresno, CA
Book an appointment for a calm, structured plan—medication options discussed only when appropriate.
Book Appointment
References
  1. FDA — GLP-1 safety communications: View
  2. Wilding JPH et al. — Semaglutide in adults with overweight/obesity (STEP 1, NEJM 2021): View
  3. CDC — Obesity and related health risks: View
  4. NIDDK — Overweight & obesity / weight management: View
Educational note: general information only; not individualized medical advice.